OrganOx
Generated by Meeveem AI
"Pioneering organ preservation technology that makes every donated organ count"
Oxford
•51 - 250 Employees
•Medical Devices
About OrganOx
OrganOx develops advanced organ preservation technology for transplantation. The company's flagship product, OrganOx metra, uses normothermic machine perfusion to maintain donor livers in near physiologic conditions for up to 12 hours. This enables clinicians to assess organ viability more accurately, reduces discard rates, and allows transplant centres to schedule procedures as planned operations. Founded in 2008 as a spinout from the University of Oxford, OrganOx serves transplant centres worldwide and was acquired by Terumo Corporation in 2025. The technology has been used in over 6,000 liver transplant procedures and continues shaping the future of organ transplantation through kidney perfusion research.
210
Team Members
2008
Founded
Medical Devices
Sector
Hybrid
Work Environment
Our Vision
A world where every donated organ is transplanted successfully, where new therapies treat diseased organs before transplant, and where technology minimises the need for transplantation by enabling earlier medical interventions.
Our Mission
OrganOx exists to save lives by making every donated organ count, developing organ preservation technology that enables clinicians to assess viability accurately and transplant more organs successfully.